Lasmiditan succinate (Synonyms: COL-144, LY573144) |
| Catalog No.GC25563 |
Lasmiditan succinate (COL-144, LY573144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (Ki=2.21 nM) without vasoconstrictor activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 439239-92-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lasmiditan succinate (COL-144, LY573144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (Ki=2.21 nM) without vasoconstrictor activity.
Lasmiditan shows higher selectivity for the 5-HT(1F) receptor relative to other 5-HT(1) receptor subtypes than the first generation 5-HT(1F) receptor agonist LY334370[1].
Lasmiditan is orally active in two in vivo models of migraine that involve electrical stimulation of the trigeminal ganglion. After oral administration, lasmiditan potently decreases dural plasma protein extravasation and the number of c-fos positive cells in the trigeminal nucleus caudalis at a dose of 3 mg/kg[1].
[1] Nelson DL, et al. Cephalalgia. 2010, 30(10):1159-69.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *